Time delays in the diagnosis and treatment of acute myocardial infarction: a tale of eight cities. Report from the Pre-hospital Study Group and the Cincinnati Heart Project.

To establish the magnitude of prehospital and hospital delays in initiating thrombolytic therapy for acute myocardial infarction, the time from telephone 911 emergency medical system (EMS) activation to treatment and its components were analyzed from eight separate ongoing trials. This included estimates of ambulance response time, prehospital evaluation and treatment time, and time from admission to the hospital to initiation of thrombolytic therapy. The average time from EMS activation to patient arrival at the hospital was prospectively determined to be 46.1 +/- 8.2 minutes in 3715 patients from eight centers. The time from admission to the hospital to initiation of thrombolytic therapy was retrospectively determined to be 83.8 +/- 55.0 minutes in a separate group of 730 patients from six centers. Both the prehospital and hospital time delays were much longer than those perceived by paramedics and emergency department directors. Shorter hospital time delays were observed in patients in whom a prehospital ECG was obtained as part of a protocol-driven prehospital diagnostic strategy and a diagnosis of acute infarction made before arrival at the hospital (36.3 +/- 11.3 minutes in 13 patients). These results show that the magnitude of time required to evaluate, transport, and initiate thrombolytic therapy will preclude initiation of treatment to most patients within the first hour of symptoms. Implementation of a protocol-driven prehospital diagnostic strategy may be associated with a reduction in time to thrombolytic therapy.

[1]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.

[2]  E. Veys,et al.  Letter: HL-A and infective sacroileitis. , 1974, Lancet.

[3]  R Roberts,et al.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.

[4]  W. Ganz,et al.  The thrombolysis in myocardial infarction (TIMI) trial. , 1985, The New England journal of medicine.

[5]  W. Weaver,et al.  Potential use of thrombolytic therapy before hospitalization. , 1989, The American journal of cardiology.

[6]  A. Jaffe,et al.  Recent changes in management of acute myocardial infarction: implications for emergency care physicians. , 1988, Journal of the American College of Cardiology.

[7]  Dwight E. Peake,et al.  Thrombolysis in myocardial infarction (TIMI) trial: Phase I. A comparison between intravenous tissue plasminogen activator and intravenous streptokinase , 1988 .

[8]  M. Gotsman,et al.  Prevention of myocardial damage in acute myocardial ischemia by early treatment with intravenous streptokinase. , 1985, The New England journal of medicine.

[9]  P. Kudenchuk,et al.  Myocardial Infarction Triage and Intervention Project--phase I: patient characteristics and feasibility of prehospital initiation of thrombolytic therapy. , 1990, Journal of the American College of Cardiology.

[10]  K. Lee,et al.  A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. , 1989, Circulation.

[11]  R. Califf,et al.  Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction. , 1988, Circulation.

[12]  R. Collins,et al.  SIGNIFICANT REDUCTION IN MORTALITY WITH STREPTOKINASE GIVEN 7-24 HOURS AFTER PAIN ONSET , 1988, The Lancet.

[13]  T. Feldman,et al.  Evaluation of patients for the need of thrombolytic therapy in the prehospital setting. , 1989, Annals of emergency medicine.

[14]  K. Lee,et al.  A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. , 1987, The New England journal of medicine.

[15]  E. Braunwald Enhancing thrombolytic efficacy by means of "front-loaded" administration of tissue plasminogen activator. , 1989, Journal of the American College of Cardiology.

[16]  M. Eisenberg,et al.  Delay between onset of chest pain and seeking medical care: the effect of public education. , 1989, Annals of emergency medicine.

[17]  David O. Williams,et al.  Improved infarct artery patency using a new modified regimen of t-PA: results of the pre-hospital administration of t-PA (PATS) pilot trial , 1990 .

[18]  J. Anderson,et al.  Impact of field-transmitted electrocardiography on time to in-hospital thrombolytic therapy in acute myocardial infarction. , 1990, The American journal of cardiology.

[19]  R. Califf,et al.  Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trial. , 1987, Journal of the American College of Cardiology.

[20]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico. LONG-TERM EFFECTS OF INTRAVENOUS THROMBOLYSIS IN ACUTE MYOCARDIAL INFARCTION: FINAL REPORT OF THE GISSI STUDY , 1987, The Lancet.

[21]  S. Sherry,et al.  Appraisal of various thrombolytic agents in the treatment of acute myocardial infarction. , 1987, The American journal of medicine.

[22]  M. Sherrid,et al.  OUT-OF-HOSPITAL, PARAMEDIC ADMINISTERED STREPTOKINASE FOR ACUTE MYOCARDIAL INFARCTION , 1988, The Lancet.

[23]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico.,et al.  EFFECTIVENESS OF INTRAVENOUS THROMBOLYTIC TREATMENT IN ACUTE MYOCARDIAL INFARCTION , 1986, The Lancet.

[24]  Harold T. Dodge,et al.  Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase* , 1987 .

[25]  Early thrombolysis in acute myocardial infarction: limitation of infarct size and improved survival. , 1986 .

[26]  E. Ruiz,et al.  An analysis of time delays preceding thrombolysis for acute myocardial infarction. , 1989, JAMA.

[27]  U. Tebbe,et al.  Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. , 1989, Journal of the American College of Cardiology.